Search results
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open
Barrons.com· 5 days agoThe drug company Pfizer said a gene therapy it is testing failed to improve motor function in boys...
FDA approves generic Emflaza oral suspension for Duchenne muscular dystrophy
Medical Xpress· 1 day agoThe U.S. Food and Drug Administration has approved the first generic version of Emflaza...
Pfizer 'can't rule out' layoffs in North Carolina after gene therapy flub - Triangle Business...
The Business Journals· 1 hour agoLayoffs could by on the way at Pfizer's massive facility in Sanford after the company's gene therapy...
Study finds LED therapy and antioxidant drug benefit muscle regeneration in Duchenne muscular ...
Medical Xpress· 4 days agoAs reported in an article published in the journal PLOS ONE, the strategy prevented muscle...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with ...
Morningstar· 6 days ago(NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene ...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 5 days agoSarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 5 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 6 days agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 5 days agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 6 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after...